| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6d77e120d1588e76c73afc1a3197a126 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57446
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3046
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-15 |
| filingDate |
2001-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2005-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c87cd34c1ba37de8dae0572b6336662a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_625cf5a5dd7208bbd55115b3d0a28608
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccee8c21bd54e60eca5954b8de9e6387
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e937f359ee48de996a495bab638a8d15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0887f1c6ddcdf6fc9e90b3d6ef3343a1 |
| publicationDate |
2005-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-I233440-B |
| titleOfInvention |
Antibodies and FV fragment that recognise IOR C2 antigen |
| abstract |
The invention is related to recombinant antibodies from murine antibody IOR C5 produced by the hybridoma deposited in the ECCC 97061101 according to the Budapest Treaty. These recombinant antibodies were obtained by recombinant DNA technology, and recognised an antigen called IOR C2. The recombinant antibodies are the chimeric and humanised antibodies, and the single chain Fv. The chimeric antibody contains the variable domains of the murine immunoglobuline and the constant regions of the human immunoglobuline. The humanised antibody contains the human constant regions and it has been modified its murine frameworks (FRs) specifically into a possible antigenic site for humanising T-cell epitopes. The Fv fragment contains the variable murine domains. This invention is also related with the use of recombinant antibodies from murine IOR C5 for the diagnosis and therapy of colorectal tumours, its metastasis and recidives. |
| priorityDate |
1999-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |